Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the <scp>ELEGANCE</scp> Study
Routine use of LECIG for up to 12 months provided sustained control of motor symptoms, and was well tolerated with a positive impact on QoL and high patient satisfaction.
Authors
- Bharat Amlani (ORCID: https://orcid.org/0000-0002-7384-7857)
- Daniel Weiß (ORCID: https://orcid.org/0000-0003-0447-7132)
- Teus van Laar (ORCID: https://orcid.org/0000-0001-5088-480X)
- Wolfgang H. Jost (ORCID: https://orcid.org/0000-0002-8574-3297)
- Harry Staines (ORCID: https://orcid.org/0000-0003-1135-5221)
- Zvezdan Pirtošek (ORCID: https://orcid.org/0000-0002-5495-944X)
- Ivan Milanov (ORCID: https://orcid.org/0000-0002-4522-4070)
- József Attila Szász (ORCID: https://orcid.org/0000-0003-1675-036X)
- Volker Tomantschger
- Norbert Kovács (ORCID: https://orcid.org/0000-0002-8532-5191)
- N J Smith
Institutions
- Royal Statistical Society (GB)
- University of Groningen (NL)
- Ljubljana University Medical Centre (SI)
- Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
- Hertie Institute for Clinical Brain Research (DE)
- Multiprofile Hospital for Active Treatment in Neurology and Psychiatry St. Naum (BG)
- Parkinson-Klinik Ortenau (DE)
- University of Pecs (HU)
Publication Details
- Journal
- Movement Disorders Clinical Practice
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1002/mdc3.70046
- Citations
- 12
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 16.67
Funders
- Britannia Pharmaceuticals